2Toornvliet R,van BBN,Luurtsema G,et al.Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C] verapamil and positron emission tomography[J].Clin Pharmacol Ther,2006,79(6):540-548.
3Wagner CC,Bauer M,Karch R,et al.A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET[J].J Nucl Med,2009,50(12):1954-1961.
4Seneca N,Zoghbi SS,Liow JS,et al.Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide,a PET radiotracer to measure the function of P-glycoprotein[J].J Nucl Med,2009,50(5):807-813.
5Takano A,Kusuhara H,Suhara T,et al.Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil[J].J Nucl Med,2006,47(9):1427-1433.
6Loscher W,Potschka H.Role of multidrug transporters in pharmacoresistance to antiepileptic drugs[J].J Pharmacol Exp Ther,2002,301(1):7-14.
7Litman T,Skovsgaard T,Stein WD.Pumping of drugs by P-glycoprotein:a two-step process[J].J Pharmacol Exp Ther,2003,307(3):846-53.
8Mastin ST,Drane WE,Gilmore RL,et al.Prospective localization of epileptogenic foci:comparison of PET and SPECT with site of surgery and clinical outcome[J].Radiology,1996,199(2):375-380.
9Langer O,Bauer M,Hammers A,et al.Pharmacoresistance in epilepsy:a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil[J].Epilepsia,2007,48(9):1774-1784.
10Hendrikse NH,Schinkel AH,de Vries EG,et al.Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography[J].Br J Pharmacol,1998,124(7):1413-1418.
